Advanced renal cell carcinoma
Trovati 11 articoli
- Microangiopathic hemolytic anemia in patients treated with Bevacizumab plus Sunitinib
- The safety and maximum tolerated dose ( MTD ) of sunitinib malate( Sutent ) in combination with Bevacizumab ( Avastin ) has been assessed in patients with metastatic renal cell carcinoma ( mRCC ) in a phase I study, exploring 3 cohorts using a fixed dose of Avastin at 10 mg/kg/IV every 2 weeks an... (Leggi Articolo)
- Acute myeloid leukemia: Nexavar targets a genetic mutation active in about one third of patients
- A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia ( AML ), the most common and lethal form of adult leukemia, researchers at The University of Texas MD Anderson Cancer Center reported in the Journal of the National... (Leggi Articolo)
- Inoperable hepatocellular carcinoma: FDA has approved Nexavar
- The FDA ( Food and Drug Administration ) has approved Nexavar ( Sorafenib ) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma,... (Leggi Articolo)
- Advanced renal cell carcinoma: Temsirolimus improves overall survival
- The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show Temsirolimus ( Torisel ) improved overall survival when compared to the current treatment for this stage of disease. The study was led by Gary R. Hudes, a... (Leggi Articolo)
- Hepatocellular carcinoma: Nexavar significantly prolongs overall survival
- Sorafenib ( Nexavar ) tablets has significantly extended overall survival in patients with hepatocellular carcinoma ( HCC ), or primary liver cancer versus those taking placebo by 44% ( HR=0.69; p-value=0.0006 ). The Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol ( SH... (Leggi Articolo)
- Advanced renal cell carcinoma: efficacy of Lapatinib in patients with high EGFR expression
- A phase III clinical trial has shown that Lapatinib ( Tykerb ) slows cancer growth and improves survival in a subset of patients with an advanced renal cell carcinoma ( RCC ) that continued to grow despite standard therapy. The patients in the study who responded favorably to this drug had tumor... (Leggi Articolo)
- Basic research at the Max Planck Institute of Biochemistry leads to a novel cancer therapy
- Axel Ullrich, at the Max Planck Institute of Biochemistry in Martinsried, Germany, already showed at the beginning of the 1990s that blocking blood vessel development in a tumour slows down its growth, and shrinks its tissue. This fundamental principle led to the development of Sutent ( Sunit... (Leggi Articolo)
- Advanced kidney cancer: Sutent shows significant benefits over Interferon-alpha
- Sunitinib ( Sutent ) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma ( mRCC ). " Sunitinib has shown more activity as a single agent against advanced kidney cancer... (Leggi Articolo)
- FDA has approved Sutent in GIST and advanced kidney cancer
- The FDA ( Food and Drug Administration ) announced approval of Sutent ( Sunitinib ), a new targeted anti-cancer treatment for patients with gastrointestinal stromal tumors ( GIST ), a rare stomach cancer, and advanced kidney cancer. Sutent is a tyrosine kinase inhibitor working through multip... (Leggi Articolo)
- Bevacizumab extends survival in non-small cell lung carcinoma
- An interim analysis of a Phase III study of Avastin ( Bevacizumab ) in combination with Paclitaxel and Carboplatin in advanced, non-small cell lung cancer ( NSCLC ) met its primary efficacy endpoint of improving overall survival, or a reduction in the risk of death, compared to chemotherapy alo... (Leggi Articolo)
- Pancreatic carcinoma: disease progression model developed
- Researchers at the University of Pennsylvania - School of Medicine have developed an animal model of pancreatic cancer that closely mimics disease progression in humans. Advanced pancreatic cancer is among the most lethal of cancers, with a one-year survival rate after chemotherapy of only 17 ... (Leggi Articolo)
